Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of “Moderate Buy” from Analysts

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $19.4545.

ORIC has been the subject of several recent research reports. Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. HC Wainwright upped their target price on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday. Stifel Nicolaus assumed coverage on shares of Oric Pharmaceuticals in a report on Friday, June 12th. They issued a “buy” rating and a $14.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Friday, July 17th. Finally, The Goldman Sachs Group upgraded shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Friday, May 15th.

Oric Pharmaceuticals Stock Performance

ORIC stock opened at $13.87 on Monday. Oric Pharmaceuticals has a one year low of $7.23 and a one year high of $14.93. The firm has a market cap of $1.44 billion, a PE ratio of -10.27 and a beta of 1.02. The firm’s 50 day moving average price is $10.72 and its 200-day moving average price is $10.53.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.02). Equities research analysts predict that Oric Pharmaceuticals will post -1.53 EPS for the current fiscal year.

Institutional Trading of Oric Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new position in shares of Oric Pharmaceuticals in the 1st quarter valued at about $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Oric Pharmaceuticals by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after purchasing an additional 3,131 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Oric Pharmaceuticals by 9.2% in the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock valued at $1,645,000 after purchasing an additional 24,778 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Oric Pharmaceuticals by 1,331.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock valued at $2,841,000 after purchasing an additional 473,600 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in Oric Pharmaceuticals by 56.0% in the first quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock valued at $174,000 after purchasing an additional 11,198 shares during the last quarter. 95.05% of the stock is owned by hedge funds and other institutional investors.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.